<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Experimental studies have shown that <z:chebi fb="0" ids="50114">estrogen</z:chebi>- or <z:chebi fb="28" ids="17026">progesterone</z:chebi>-activated signaling leads to growth inhibition effects on <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells through the upregulation of several cell-cycle regulators </plain></SENT>
<SENT sid="1" pm="."><plain>However, epidemiologic studies evaluating hormone therapy use and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk by the status of cell-cycle regulators are lacking </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we used data from the prospective Nurses' Health Study to evaluate whether the association between hormone therapy use and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk differs by the molecular pathologic status of microsatellite instability (MSI) and expression of cell-cycle-related <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biomarkers, including CDKN1A (p21, CIP1), CDKN1B (p27, KIP1), and TP53 (p53) by immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>Duplication Cox regression analysis was used to determine an association between hormone therapy use, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk, and specific <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biomarkers in 581 incident colon and <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> cases that occurred during 26 years of follow-up among 105,520 postmenopausal women </plain></SENT>
<SENT sid="4" pm="."><plain>We found a difference between hormone therapy use and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk according to CDKN1A expression (P(<z:hpo ids='HP_0001425'>heterogeneity</z:hpo>) = 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>Current hormone therapy use was associated with a reduced risk for CDKN1A-nonexpressed [multivariate relative risk (RR), 0.61; 95% confidence interval (CI), 0.46-0.82] but not for CDKN1A-expressed (RR, 1.32; 95% CI, 0.76-2.31) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The lower risk for CDKN1A-nonexpressed but not for CDKN1A-expressed <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> was also present among current users of <z:chebi fb="0" ids="50114">estrogen</z:chebi>-alone therapy </plain></SENT>
<SENT sid="7" pm="."><plain>We found no significant difference in the relations between hormone therapy use and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk according to MSI, CDKN1B, or TP53 status </plain></SENT>
<SENT sid="8" pm="."><plain>Together, our molecular pathological epidemiology findings suggest a preventive effect of hormone therapy against colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> that depends, in part, on loss of cyclin-dependent kinase inhibitor CDKN1A </plain></SENT>
</text></document>